HEB News and Press, Hemispherx BioPharma Inc. From 05/06/19

OCALA, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases — and whose product portfolio includes Amp...

NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Hemispherx Biopharma, Inc. (NYSE: HEB) , a specialty pharmaceutical company, eng...

OCALA, Fla., April 30, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today significant progress in its Ampligen recurrent ovaria...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio...

OCALA, Fla., April 25, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today that CEO Thomas K. Equels will present at the Planet MicroCap Showcase on Wednesday...

We are pleased to announce the release of the MicroCap Review Magazine Spring 2019 issue online and in print. Click here to read: MicroCap Review Spring 2019 The Spring 2019 issue of MicroCap Review, includes new content from our list of expert writers and opinion leaders, as well as...

OCALA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced the appointment of Ellen Lintal as the company’s n...

OCALA, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, N.Y. evaluating Hemispherx’ experimental drug Ampligen ...

Hemispherx Biopharma (NYSEMKT: HEB ): FY GAAP EPS of -$0.22. More news on: Hemispherx Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...